<!DOCTYPE html>
<html lang="en"><head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1" name="viewport"/>
<link href="https://cdn-icons-png.flaticon.com/512/4021/4021693.png" rel="icon"/>
<link href="../style.css" rel="stylesheet"/>
<link href="https://fonts.googleapis.com" rel="preconnect"/>
<link crossorigin="" href="https://fonts.gstatic.com" rel="preconnect"/>
<link href="https://fonts.googleapis.com/css2?family=Inter:wght@300;400;500;600&amp;family=Space+Mono:wght@400;700&amp;display=swap" rel="stylesheet"/>
<title>Azithromycin</title>
</head><body><main class="container"><header class="site-header">
<h1 class="logo"><a href="../index.html">r/anhedonia</a></h1>
<p class="subtitle">Personal Wiki</p>
</header><nav style="margin-bottom: 20px;"><a href="../actions.html">← Back to Personal Wiki</a></nav><section class="card"><h2>Azithromycin</h2><ul>
<li><img src="https://upload.wikimedia.org/wikipedia/commons/thumb/6/6e/Azithromycin.svg/250px-Azithromycin.svg.png"/></li>
<li>Pharmacological Actions and Mechanisms</li>
<li>Azithromycin's primary pharmacological action is as a bacteriostatic antibiotic, inhibiting bacterial protein synthesis by binding to the 50S ribosomal subunit, specifically the 23S rRNA, which prevents transpeptidation and translocation. This action is crucial for treating infections caused by susceptible bacteria, such as Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae. Additionally, research suggests Azithromycin has immunomodulatory effects, reducing inflammation, which has been explored for chronic respiratory conditions like asthma, though responsiveness varies with individual lung microbiome composition.</li>
<li>The mechanism also includes inhibition of Protein-arginine deiminase type-4 in humans, though its clinical significance is less clear. These actions contribute to its broad-spectrum antibacterial activity and potential anti-inflammatory benefits, particularly in long-term use scenarios.</li>
<li>Timing of Pharmacological Actions</li>
<li>The timing of Azithromycin's effects is influenced by its pharmacokinetics. After oral administration, peak plasma concentrations are typically reached in 2-3 hours, reflecting rapid absorption. Its long terminal elimination half-life of approximately 68 hours allows for sustained antibacterial activity, with tissue concentrations remaining above the minimum inhibitory concentration (MIC) for susceptible bacteria for several days post-treatment. This prolonged presence supports once-daily dosing and shorter treatment courses compared to other antibiotics. The immunomodulatory effects, while less studied for timing, likely manifest over days to weeks, given their role in chronic conditions, but specific onset times are not well-documented in the literature.</li>
<li>Pharmacokinetics and Bioavailability</li>
<li>Azithromycin's pharmacokinetics are characterized by:</li>
<ul>
<li>Absorption: Oral bioavailability is approximately 37-38%, mediated by P-glycoprotein (ABCB1) efflux transporters, and is not significantly affected by food.</li>
<li>Distribution: It has a high volume of distribution (31.1 L/kg), with significant penetration into tissues such as lungs, tonsils, prostate, and phagocytes, contributing to its efficacy against intracellular pathogens.</li>
<li>Protein Binding: Serum protein binding decreases from 51% at 0.02 µg/mL to 7% at 2 µg/mL, affecting free drug levels.</li>
<li>Metabolism and Elimination: Primarily eliminated via biliary excretion as unchanged drug, with about 6% excreted in urine over a week, and a mean apparent plasma clearance of 630 mL/min.</li>
</ul>
<li>The long half-life (68 hours for a 3-day regimen, 71.8 hours for a 5-day regimen) underscores its extended duration of action, supporting its use in shorter treatment durations.</li>
<li>Dosage Regimens</li>
<li>Dosage varies by indication, patient age, and condition severity, as outlined in Table 1 below:</li>
<li><table>
<tr>
<th>Condition</th>
<th>Adult Dosage</th>
<th>Pediatric Dosage (Weight-Based)</th>
</tr>
<tr>
<td>Community-Acquired Pneumonia</td>
<td>500 mg Day 1, then 250 mg daily Days 2-5</td>
<td>10 mg/kg Day 1, then 5 mg/kg Days 2-5</td>
</tr>
<tr>
<td>Acute Bacterial Sinusitis</td>
<td>500 mg daily for 3 days</td>
<td>10 mg/kg daily for 3 days</td>
</tr>
<tr>
<td>Pharyngitis/Tonsillitis</td>
<td>500 mg Day 1, then 250 mg daily Days 2-5</td>
<td>12 mg/kg daily for 5 days, max 500 mg/day</td>
</tr>
<tr>
<td>Genital Ulcer Disease</td>
<td>1 g single dose</td>
<td>Not typically indicated</td>
</tr>
<tr>
<td>Gonococcal Urethritis/Cervicitis</td>
<td>2 g single dose</td>
<td>Not typically indicated</td>
</tr>
<tr>
<td>Acute Otitis Media</td>
<td>Not standard for adults</td>
<td>30 mg/kg single dose or 10 mg/kg for 3 days</td>
</tr>
</table></li>
<ul>
<li>Safe Range: Doses within these regimens are generally considered safe for patients without contraindications, such as known hypersensitivity to macrolides or history of cholestatic jaundice with prior use.</li>
<li>Minimum Effective Dose: Varies by condition; for example, a single 1 g dose is effective for uncomplicated chlamydia, while for community-acquired pneumonia, the regimen starting at 500 mg is standard.</li>
<li>Maximum Safe Dose: The highest recommended single dose is 2 g for gonococcal infections, with daily doses typically not exceeding 500 mg for most conditions. Long-term prophylaxis may involve 500 mg three times weekly.</li>
<li>LD50: Not established for humans; in rats, it's &gt;2000 mg/kg, indicating a wide therapeutic index, but human toxicity is more related to adverse effects than acute lethality.</li>
</ul>
<li>Safety, Toxicity, and Risk Thresholds</li>
<li>Azithromycin's safety profile includes common side effects like diarrhea (5-14%), nausea (3-18%), and abdominal pain (3-7%), with serious risks including QT prolongation, hepatotoxicity, and severe allergic reactions. Research suggests toxicity manifests at higher doses, particularly in vulnerable populations:</li>
<ul>
<li>Liver toxicity can include transient transaminase elevations (1-2%) or cholestatic hepatitis, often resolving within 4-8 weeks.</li>
<li>QTc prolongation, linked to potential torsades de pointes, is a concern, especially in patients with pre-existing heart conditions or coadministered drugs affecting CYP 3A4.</li>
<li>Case reports, such as a 9-month-old infant receiving 50 mg/kg (about 5 times the usual dose), highlight life-threatening bradycardia and heart block, leading to severe outcomes like anoxic encephalopathy.</li>
</ul>
<li>It seems likely that doses significantly above recommended levels, particularly in those with risk factors, start becoming too dangerous, with cardiac and hepatic effects increasing. For adults, exceeding daily doses of 500 mg, especially in long-term use, or taking single doses above 2 g without medical supervision, could elevate risks, though exact thresholds are patient-specific.</li>
</ul></section><footer class="site-footer">
<p><a href="../index.html">← Back to Home</a></p>
</footer></main></body></html>